Erratum to “Consolidative thoracic radiotherapy in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts” [Radiother. Oncol. 135 (2019) 74–77]

The publisher regrets that in the abovementioned article, an author name was listed incorrectly. The correct author listing is presented above. The publisher would like to apologise for any inconvenience caused. Consolidative thoracic radiotherapy in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO expertsRadiotherapy and OncologyVol. 135PreviewAs a standard of care, patients with stage IV SCLC receive four to six cycles of palliative chemotherapy (platinum/etoposide). The Impower 133 trial has shown improvement of progression-free survival (PFS) and overall survival (OS) when adding atezolizumab to carboplatin/etoposide and this regimen may become a new standard of care in suitable patients [1]. Full-Text PDF